Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

NCT07449923 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07449923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07449923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 9, 2026
Completion date
October 31, 2028
Enrollment
240 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic macular edema (dme), dme